65% improvement is huge. Imagine what just 30% would mean to a stage 4 patient. So far there are many monoclonal PD1 inhibitors trialed and a few on the market selling for multi billion USD. But almost all come with serious side effects, don't last unless constantly re-administered and have no observed / reported triggered immune system memory effect. From my research only IVX 043 pre-clinical and IMU's CF33 / Her-Vaxx and PD1-Vaxx in clinical trials have ever achieved that.
GLTA
IVX Price at posting:
1.0¢ Sentiment: Buy Disclosure: Held
